A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- Conditions
- Hidradenitis SuppurativaAtopic Dermatitis
- Registration Number
- NCT06524635
- Lead Sponsor
- AbbVie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria:<br><br> - Sub-Study 1 hidradenitis suppurativa (HS):<br><br> - Participants with a diagnosis of moderate-to-severe HS for at least 6 months prior<br> to Baseline as determined by the investigator<br><br> - Participants naïve to biologic treatment for HS or must have a prior inadequate<br> response or loss of response to anti-TNF therapy for HS (>= 12 weeks of therapy).<br><br> - Sub-Study 2 atopic dermatitis (AD):<br><br> - Participants with a diagnosis of moderate-to-severe AD with onset of symptoms at<br> least 1 year prior to Baseline.<br><br> - Participants naïve to biologic treatment for AD or must have a prior inadequate<br> response or loss of response to dupilumab for AD (defined as >= 8 weeks of therapy<br> with dupilumab).<br><br>Exclusion Criteria:<br><br> - History of any malignancy within the last 5 years except for successfully treated<br> nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.<br><br> - History of active skin disease (other than HS for Sub-Study 1 or AD for Sub-Study 2)<br> that could interfere with the assessment of HS (for Sub-Study 1) or AD (for<br> Sub-Study 2), including skin infections (e.g., bacterial, fungal, or viral)<br> requiring systemic treatment within 4 weeks of the Baseline.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants With Adverse Events (AEs)
- Secondary Outcome Measures
Name Time Method